August 9, 2017 5:09pm


After the am post mentioned, “Buying the dips that keep dipping”


The IBB is down -0.32% with the XBI -0.52% and IWM -0.86% while the XLV +0.11% and VIX +2.10% are up


Are markets responding to geo-political tensions or reacting to overbought conditions?


Pre-open indications: 4 hit and 2 miss



It’s called premium content for a reason … I define insight  from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!

Others don’t even come close!


I answer one question, in which company should investors commit and keep their money.



Wednesday’s results have implications to Thursday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!




From the pre-open’s investor’s newsletter, “… buying the dips that keeps - dipping; it isn’t the momentum you want to ride.”

  • Sticking to my premise - Volume on advancing stocks versus declining stocks as always has its ebb and flow however, market breath … stinks! It’s hot one day and stinks to high heaven two ahead.

As I stated, “So where does that leave the cell therapy sector … that is being “run” by algorithms, exposed by ETFs, managed by day traders and hedge funds … as mutual funds and retail brokers … CAN’T invest <in most cases> in an equity below $5.00!”

  • The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, hit a one-month high.

For all these variables – political market, sector and Q2 results being announced; to move “our” universe will require an actual act of friendliness and approachability —to balance any reaction for anything to be pronounced.


This is NOT … YET … a buying opportunity" in cell therapy stocks; today's dipping reaction is NOT short lived and those that shot-up will be dethroned.

By the end of next week could we consider the outcomes of Q2 results …



The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The first hour was positive with an A/DL of 26/15 and 2 flat;

·         The mid-day was negative with an A/DL of 15/25 and 3 flat;

·         The close was negative  with an A/DL of 10/31 and 2 flats;



Pre-open indications:  4 hit and 2 miss

  • Athersys (ATHX) closed down -$0.02 – hit;
  • Biostage (BSTG) closed down -$0.03 – hit;
  • BioLife Solutions (BLFS) closed down -$0.05 – hit;
  • Bellicum Pharmaceuticals (BLCM) closed down -$2.27 – hit;
  • bluebird bio (BLUE) closed down -$0.35 – miss;
  • Kite Pharma (KITE) closed up +$0.85 – miss;



Regenerative Medicine Earnings Scorecard - Q2/2017 - to date …

Added today: VCEL, FCSC, SGMO, ATHX, XON and ONVO



Daily analytics:

U.S. stocks closed down Wednesday, but off session lows as tensions between North Korea and the U.S. added a dollop of geopolitical uncertainty to markets.

The Dow declined 36.64 points, or 0.2%, to close at 22,048.70, after briefly losing its grip on the psychological milestone of 22,000.

The S&P 500 index slipped 0.90 point, or less than 0.1%, to finish at 2,474.02, overcoming an earlier 13-point deficit.  The NASDAQ closed down 18.13 points, or 0.3%, at 6,352.33, paring an earlier 61-point decline.



The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Wednesday traded at 11.19, up +2.10%

  • Tuesday traded at 11.03, up +11.08% after Monday traded at 9.93 … down -1% after Friday traded at 10.03 – down -3.93% … after Thursday traded at 10.44, up +1.56%  and last Wednesday traded at 10.24, up +1.49%


Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Wednesday was down -0.86%

·         Tuesday  -0.31%

·         Monday +0.16%

·         Friday  +0.49%

·         Thursday  -0.51%

·         Last Wednesday -1.07%

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Wednesday was down -0.32%

·         Tuesday -9,94%

·         Monday +0.54%

·         Friday +0.33%

·         Thursday -0.79%

·         Last Wednesday +0.40% which didn’t help the cell therapy sector



The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %’s migrate…

·         Wednesday’s decliners ranged from -0.16% <OSIR> to -21.24% <BLCM> in 31 equities;

·         Tuesday’s decliners ranged from -0.46% <BCLI> to -11.11% <CUR> in 28 equities;

·         Monday’s decliners ranged from -0.21% <CLLS> to -16.07% <NWBO> in 17 equities;

·         Friday’s decliners ranged from -0.14% <MDXG> to -13.24% <CUR> in 15 equities;

·         Thursday’s decliners ranged from -0.53% <HSGX> to -6.85% <CUR> in 18 equities;

·         Last Wednesday’s decliners ranged from -0.15% <OSIR> to -9.63% <CYTX> in 28 equities;



… Look at the percentage’s (%) and spreads …

·         Wednesday’s gainers ranged from +0.71% <KITE> to +13.33% <VCEL> in 10 equities;

·         Tuesday’s gainers ranged from +0.19%  <ONCE> to +5.79% <KITE> in 14 equities;

·         Monday’s gainers ranged from +0.12%  <IMUC> to +30.43% <BSTG> in 22 equities;

·         Friday’s gainers ranged from +0.14%  <ONCE> to +13.43% <RENE.L> in 24 equities;

·         Thursday’s gainers ranged from +0.30%  <CLLS> to +10.91% <CAPR> in 20 equities;

·         Last Wednesday’s gainers ranged from +0.64%  <QURE> to +19.72% <ONCE> in 14 equities;



Some of MY working trend lines or indications:

… The greatest volume to the downside:  BLCM, MDXG, IMUC, VSTM and SGMO

… Upside volume was weighted to:  KITE, VCEL, XON, JUNO and RGNX

… Biggest $ downside:  BLCM, ONCE, AXGN, CLLS and STML

… Largest $ upside:  KITE, JUNO, VCEL, XON and QURE

… Flat: NWBO and BTX



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.